Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22726571 | 1.00 | UCHL1 (0.41) | UCHL1MALT1PIK3CAPIK3R1ROCK2 | |
| SCHEMBL30855205 | 0.85 | UCHL1 (0.41) | UCHL1MALT1PIK3CAPIK3R1ROCK2 | |
| SCHEMBL29333868 | 0.85 | UCHL1 (0.41) | UCHL1MALT1PIK3CAPIK3R1ROCK2 | |
| SCHEMBL22726599 | 0.84 | UCHL1 (0.52) | UCHL1ROCK2 | |
| SCHEMBL29953798 | 0.84 | UCHL1 (0.52) | UCHL1ROCK2 | |
| SCHEMBL24707503 | 0.83 | NR1H2 (0.41) | UCHL1MALT1PIK3CAPIK3R1USP2 | |
| SCHEMBL30001333 | 0.83 | NR1H2 (0.41) | UCHL1MALT1PIK3CAPIK3R1USP2 | |
| SCHEMBL3398447 | 0.82 | NR1H2 (0.45) | MALT1USP2SMN1; SMN2PIK3CDNR1H2 | |
| SCHEMBL3398450 | 0.82 | NR1H2 (0.45) | MALT1USP2SMN1; SMN2PIK3CDNR1H2 | |
| SCHEMBL2386023 | 0.82 | NR1H2 (0.43) | MALT1PIK3CAPIK3R1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | ONCO3R THERAPEUTICS BV (BE) | 2025-08-19 | — | — | US | disclosed |
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1B, IL1A, IL36G | UCHL1 3857/4885MALT1 3201/4885PIK3CA 1294/4885 |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | IL5, IL15, IL1A | UCHL1 4521/4885MALT1 3426/4885PIK3CA 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.